Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer

Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. Objective: We sought to evaluate the effectiveness of an...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 100; no. 10; pp. 3887 - 3893
Main Authors Sim, Ie-Wen, Sanders, Kerrie M, Borromeo, Gelsomina L, Seymour, John F, Ebeling, Peter R
Format Journal Article
LanguageEnglish
Published United States Endocrine Society 01.10.2015
Copyright by The Endocrine Society
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. Objective: We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. Design and Setting: We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. Main Outcome Measures: The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. Results: A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ2 = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). Conclusion: The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ.
AbstractList Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. Objective: We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. Design and Setting: We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. Main Outcome Measures: The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. Results: A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ2 = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). Conclusion: The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ.
CONTEXT:Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. OBJECTIVE:We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. DESIGN AND SETTING:We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. MAIN OUTCOME MEASURES:The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. RESULTS:A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). CONCLUSION:The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ.
Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ(2) = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ.
CONTEXTMedication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial.OBJECTIVEWe sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence.DESIGN AND SETTINGWe identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database.MAIN OUTCOME MEASURESThe incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared.RESULTSA total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ(2) = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004).CONCLUSIONThe likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ.
Author Sim, Ie-Wen
Borromeo, Gelsomina L
Seymour, John F
Ebeling, Peter R
Sanders, Kerrie M
AuthorAffiliation Western Campus, Melbourne Medical School (I.-W.S., K.M.S.), University of Melbourne, St Albans, Victoria 3021, Australia; Department of Endocrinology (I.-W.S.), Western Health, Melbourne, Victoria 3021, Australia; Department of Endocrinology (I.-W.S., P.R.E.), Monash Health, Melbourne, Victoria 3168, Australia; Institute of Health and Ageing (K.M.S.), Australian Catholic University, Melbourne, Victoria 3000, Australia; Melbourne Dental School (G.L.B.), University of Melbourne, Carlton, Victoria 3053, Australia; Department of Haematology (J.F.S.), Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, East Melbourne, Victoria 3002, Australia; and Department of Medicine (P.R.E.), School of Clinical Sciences, Monash University, Melbourne, Victoria 3168, Australia
AuthorAffiliation_xml – name: Western Campus, Melbourne Medical School (I.-W.S., K.M.S.), University of Melbourne, St Albans, Victoria 3021, Australia; Department of Endocrinology (I.-W.S.), Western Health, Melbourne, Victoria 3021, Australia; Department of Endocrinology (I.-W.S., P.R.E.), Monash Health, Melbourne, Victoria 3168, Australia; Institute of Health and Ageing (K.M.S.), Australian Catholic University, Melbourne, Victoria 3000, Australia; Melbourne Dental School (G.L.B.), University of Melbourne, Carlton, Victoria 3053, Australia; Department of Haematology (J.F.S.), Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, East Melbourne, Victoria 3002, Australia; and Department of Medicine (P.R.E.), School of Clinical Sciences, Monash University, Melbourne, Victoria 3168, Australia
Author_xml – sequence: 1
  givenname: Ie-Wen
  surname: Sim
  fullname: Sim, Ie-Wen
  email: simi@unimelb.edu.au
– sequence: 2
  givenname: Kerrie M
  surname: Sanders
  fullname: Sanders, Kerrie M
– sequence: 3
  givenname: Gelsomina L
  surname: Borromeo
  fullname: Borromeo, Gelsomina L
– sequence: 4
  givenname: John F
  surname: Seymour
  fullname: Seymour, John F
– sequence: 5
  givenname: Peter R
  surname: Ebeling
  fullname: Ebeling, Peter R
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26241323$$D View this record in MEDLINE/PubMed
BookMark eNptkE2PFCEQholZ486u3jwbjh5k5avp4Whm_VizZo3RaLwQGqodxh4Ygc7Efy-dWT1JUiEkT71FPRfoLKYICD1l9IpxRl_u3BWnrCOs1_IBWjEtO9Iz3Z-hFaWcEd3zb-foopQdpUzKTjxC51xxyQQXK_T9GtwUYog_8E10wUN0gNOIP4APztaQIvkEk63g8V2p0Ea7nEooC1O3gN_bIw4Rf2woxFrw11C3eGNbSn6MHo52KvDk_r5EX968_rx5R27v3t5sXt0SJ6VUZOgVd3ropHJqLdeSW0EF1dzZtQM_cj9qqZUYfUcHGJTjA9MdeOekdloILy7R81PuIadfM5Rq9qE4mCYbIc3FsJ5T2XGpZUNfnNBliZJhNIcc9jb_NoyaxabZObPYNIvNhj-7T56HPfh_8F99DZAn4JimCrn8nOYjZLMFO9Wtoe1I1a_JksiWF2klVGsTpzaIPrkcIhwylGJ2ac6xqfr_b_4ALMyR4g
CitedBy_id crossref_primary_10_1038_s41368_020_00093_2
crossref_primary_10_1002_JPER_21_0611
crossref_primary_10_1016_j_ajoms_2017_08_004
crossref_primary_10_1016_j_jfma_2021_01_015
crossref_primary_10_1186_s12913_024_10859_7
crossref_primary_10_1097_GME_0000000000001393
crossref_primary_10_1185_03007995_2016_1170005
crossref_primary_10_3390_dj4040032
crossref_primary_10_1007_s11838_023_00176_w
crossref_primary_10_1016_j_clgc_2018_05_003
crossref_primary_10_1210_jc_2018_01965
crossref_primary_10_1016_j_jsps_2020_05_004
crossref_primary_10_3238_arztebl_2017_0063
crossref_primary_10_1016_j_bone_2021_115866
crossref_primary_10_1111_odi_12966
crossref_primary_10_1200_JCO_19_01186
crossref_primary_10_1200_JCO_19_02192
crossref_primary_10_1016_j_sdentj_2022_01_003
crossref_primary_10_1007_s12285_016_0063_4
crossref_primary_10_1111_odi_12842
crossref_primary_10_3390_medicina59030535
crossref_primary_10_1097_SCS_0000000000009033
crossref_primary_10_1200_JCO_20_01633
crossref_primary_10_1007_s00774_020_01195_x
crossref_primary_10_1007_s00520_022_06839_4
crossref_primary_10_1016_j_ctrv_2018_06_007
crossref_primary_10_1007_s11428_017_0235_5
crossref_primary_10_1200_JOP_19_00384
crossref_primary_10_32388_MZJDOX
crossref_primary_10_1016_j_bone_2020_115412
crossref_primary_10_1177_0192623317737066
ContentType Journal Article
Copyright Copyright © 2015 by the Endocrine Society
Copyright © 2015 by The Endocrine Society
Copyright_xml – notice: Copyright © 2015 by the Endocrine Society
– notice: Copyright © 2015 by The Endocrine Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1210/jc.2015-1794
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 3893
ExternalDocumentID 10_1210_jc_2015_1794
26241323
00004678-201510000-00036
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
02
08R
0R
1TH
29K
2WC
34G
39C
3O-
3V.
4.4
48X
53G
55
5GY
5RS
5YH
7X7
88E
8F7
8FI
8FJ
AABJS
AABMN
AAIMJ
AAJQQ
AAPQZ
AAQQT
AAUQX
AAWTL
AAYJJ
ABFLS
ABOCM
ABPMR
ABPPZ
ABSAR
ABUWG
ACGFS
ACIMA
ACPRK
ACUTJ
ADBBV
ADBIT
ADEIU
ADGZP
ADHKW
ADRTK
AELNO
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFNX
AFKRA
AFRAH
AFXEN
AGINJ
AGKRT
AGVJH
AHMBA
AIKOY
AIMBJ
ALMA_UNASSIGNED_HOLDINGS
APIBT
AQKUS
ARIXL
ASMCH
ASPBG
AVWKF
AYOIW
AZFZN
AZQFJ
BAWUL
BAYMD
BBAFP
BCRHZ
BENPR
BEYMZ
BGYMP
BHONS
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CDBKE
CS3
D-I
DAKXR
DIK
DPPUQ
E3Z
EBS
EIHJH
EJD
ENERS
F5P
FEDTE
FH7
FHSFR
FOTVD
FQBLK
FYUFA
G8K
GAUVT
GJ
GJXCC
GX1
H1
H13
HVGLF
HZ
H~9
IAO
IHR
INH
J5H
KBUDW
KOP
KQ8
KSN
L7B
M1P
M5
MBLQV
MHKGH
N9A
NLBLG
NOYVH
NVLIB
O0-
O9-
OBH
OCB
ODMLO
OGEVE
OK1
OVD
P2P
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
REU
ROX
ROZ
TCN
TJX
TLC
TMA
TWZ
VH1
WOQ
X
X52
X7M
XZ
ZA5
ZGI
ZXP
ZY1
.XZ
3RD
AJYGW
M2M
M5~
ROL
~H1
---
-~X
.55
.GJ
08P
0R~
18M
354
AABZA
AACZT
AAKAS
AAPGJ
AAPXW
AARHZ
AAUAY
AAVAP
AAWDT
ABBLC
ABJNI
ABLJU
ABMNT
ABNHQ
ABPQP
ABPTD
ABQNK
ABWST
ABXVV
ACFRR
ACGFO
ACYHN
ACZBC
ADGKP
ADQBN
ADVEK
ADZCM
AERZD
AFFZL
AFGWE
AFOFC
AFXAL
AFYAG
AGMDO
AGQXC
AGUTN
AI.
AJEEA
APJGH
AQDSO
ATGXG
AVNTJ
CGR
CUY
CVF
ECM
EIF
EMOBN
FECEO
FLUFQ
FOEOM
HZ~
ITC
KSI
MJL
N4W
NOMLY
NPM
OAUYM
OFXIZ
OHH
OJZSN
OPAEJ
OVIDX
P6G
TEORI
TR2
VVN
W8F
WHG
YBU
YFH
YHG
YOC
YSK
~02
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4446-b762c9b546c684842a303092ca8cedf2df94963fd50beb6c2b195edcc49c933d3
ISSN 0021-972X
IngestDate Fri Aug 16 21:50:44 EDT 2024
Thu Sep 26 18:32:35 EDT 2024
Sat Sep 28 08:03:23 EDT 2024
Thu Aug 13 19:54:33 EDT 2020
Tue Jan 05 21:44:44 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4446-b762c9b546c684842a303092ca8cedf2df94963fd50beb6c2b195edcc49c933d3
Notes The National Health and Medical Research Council of Australia supports I.-W.S.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/jcem/article-pdf/100/10/3887/10424467/jcem3887.pdf
PMID 26241323
PQID 1720452494
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1720452494
crossref_primary_10_1210_jc_2015_1794
pubmed_primary_26241323
wolterskluwer_health_00004678-201510000-00036
endocrinepress_journals_10_1210_jc_2015_1794
ProviderPackageCode .XZ
OBH
C45
5RS
AFCHL
OGEVE
~H1
ABPMR
M5~
OVD
OCB
PublicationCentury 2000
PublicationDate 2015-October
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-October
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2015
Publisher Endocrine Society
Copyright by The Endocrine Society
Publisher_xml – name: Endocrine Society
– name: Copyright by The Endocrine Society
References López-Jornet, P; Camacho-Alonso, F; Martínez-Canovas, A; Molina-Miñano, F; Gómez-García, F; Vicente-Ortega, V (B30) 2011; 69
Marx, RE (B20) 2003; 61
Coxon, FP; Thompson, K; Rogers, MJ (B26) 2006; 6
Miksad, RA; Lai, KC; Dodson, TB (B12) 2011; 16
Van den Wyngaert, T; Huizing, MT; Fossion, E; Vermorken, JB (B17) 2009; 14
La Verde, N; Bareggi, C; Garassino, M (B25) 2008; 16
Wilkinson, GS; Kuo, YF; Freeman, JL; Goodwin, JS (B9) 2007; 99
Boonyapakorn, T; Schirmer, I; Reichart, PA; Sturm, I; Massenkeil, G (B21) 2008; 44
Dimopoulos, MA; Kastritis, E; Bamia, C (B23) 2009; 20
Khosla, S; Burr, D; Cauley, J (B1) 2007; 22
(B15) 2007; 65
Maerevoet, M; Martin, C; Duck, L (B28) 2005; 353
Hoff, AO; Toth, BB; Altundag, K (B3) 2008; 23
Tsao, C; Darby, I; Ebeling, PR (B10) 2013; 71
Mavrokokki, T; Cheng, A; Stein, B; Goss, A (B22) 2007; 65
Sambrook, PJ; Nordin, BE; Goss, AN (B11) 2011; 194
Ripamonti, CI; Maniezzo, M; Campa, T (B24) 2009; 20
Ruggiero, SL; Dodson, TB; Fantasia, J (B2) 2014; 72
Santini, D; Fratto, ME; Vincenzi, B; La Cesa, A; Dianzani, C; Tonini, G (B18) 2004; 18
Cheung, A; Seeman, E (B13) 2010; 363
Raj, DV; Abuzar, M; Borromeo, GL (B14)
Stopeck, AT; Lipton, A; Body, JJ (B29) 2010; 28
Durie, BG; Katz, M; Crowley, J (B5) 2005; 353
Fizazi, K; Carducci, M; Smith, M (B7) 2011; 377
Ruggiero, SL; Dodson, TB; Assael, LA; Landesberg, R; Marx, RE; Mehrotra, B (B16) 2009; 67
Dickinson, M; Prince, HM; Kirsa, S (B8) 2009; 39
Santini, D; Vespasiani Gentilucci, U; Vincenzi, B (B19) 2003; 14
Fleisch, H (B27) 1998; 19
Mawardi, H; Giro, G; Kajiya, M (B31) 2011; 90
Hoff, AO; Toth, B; Hu, M; Hortobagyi, GN; Gagel, RF (B4) 2011; 1218
Henry, DH; Costa, L; Goldwasser, F (B6) 2011; 29
References_xml – ident: B14
  article-title: Bisphosphonates, healthcare professionals and oral health [published online July 15, 2014]
  publication-title: Gerodontology
  contributor:
    fullname: Raj, DV; Abuzar, M; Borromeo, GL
– volume: 14
  start-page: 181
  year: 2009
  end-page: 191
  ident: B17
  article-title: Bisphosphonates in oncology: rising stars or fallen heroes
  publication-title: Oncologist
  contributor:
    fullname: Van den Wyngaert, T; Huizing, MT; Fossion, E; Vermorken, JB
– volume: 16
  start-page: 121
  year: 2011
  end-page: 132
  ident: B12
  article-title: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw
  publication-title: Oncologist
  contributor:
    fullname: Miksad, RA; Lai, KC; Dodson, TB
– volume: 99
  start-page: 1016
  year: 2007
  end-page: 1024
  ident: B9
  article-title: Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis
  publication-title: J Natl Cancer Inst
  contributor:
    fullname: Wilkinson, GS; Kuo, YF; Freeman, JL; Goodwin, JS
– volume: 71
  start-page: 1360
  year: 2013
  end-page: 1366
  ident: B10
  article-title: Oral health risk factors for bisphosphonate-associated jaw osteonecrosis
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: Tsao, C; Darby, I; Ebeling, PR
– volume: 67
  start-page: 2
  year: 2009
  end-page: 12
  ident: B16
  article-title: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: Ruggiero, SL; Dodson, TB; Assael, LA; Landesberg, R; Marx, RE; Mehrotra, B
– volume: 20
  start-page: 117
  year: 2009
  end-page: 120
  ident: B23
  article-title: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
  publication-title: Ann Oncol
  contributor:
    fullname: Dimopoulos, MA; Kastritis, E; Bamia, C
– volume: 22
  start-page: 1479
  year: 2007
  end-page: 1491
  ident: B1
  article-title: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research
  publication-title: J Bone Miner Res
  contributor:
    fullname: Khosla, S; Burr, D; Cauley, J
– volume: 44
  start-page: 857
  year: 2008
  end-page: 869
  ident: B21
  article-title: Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies
  publication-title: Oral Oncol
  contributor:
    fullname: Boonyapakorn, T; Schirmer, I; Reichart, PA; Sturm, I; Massenkeil, G
– volume: 16
  start-page: 1311
  year: 2008
  end-page: 1315
  ident: B25
  article-title: Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution
  publication-title: Support Care Cancer
  contributor:
    fullname: La Verde, N; Bareggi, C; Garassino, M
– volume: 363
  start-page: 2473
  year: 2010
  end-page: 2474
  ident: B13
  article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw
  publication-title: N Engl J Med
  contributor:
    fullname: Cheung, A; Seeman, E
– volume: 20
  start-page: 137
  year: 2009
  end-page: 145
  ident: B24
  article-title: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
  publication-title: Ann Oncol
  contributor:
    fullname: Ripamonti, CI; Maniezzo, M; Campa, T
– volume: 377
  start-page: 813
  year: 2011
  end-page: 822
  ident: B7
  article-title: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
  publication-title: Lancet
  contributor:
    fullname: Fizazi, K; Carducci, M; Smith, M
– volume: 23
  start-page: 826
  year: 2008
  end-page: 836
  ident: B3
  article-title: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
  publication-title: J Bone Miner Res
  contributor:
    fullname: Hoff, AO; Toth, BB; Altundag, K
– volume: 19
  start-page: 80
  year: 1998
  end-page: 100
  ident: B27
  article-title: Bisphosphonates: mechanisms of action
  publication-title: Endocr Rev
  contributor:
    fullname: Fleisch, H
– volume: 65
  start-page: 369
  year: 2007
  end-page: 376
  ident: B15
  article-title: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws
  publication-title: J Oral Maxillofac Surg
– volume: 1218
  start-page: 47
  year: 2011
  end-page: 54
  ident: B4
  article-title: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients
  publication-title: Ann NY Acad Sci
  contributor:
    fullname: Hoff, AO; Toth, B; Hu, M; Hortobagyi, GN; Gagel, RF
– volume: 14
  start-page: 1468
  year: 2003
  end-page: 1476
  ident: B19
  article-title: The antineoplastic role of bisphosphonates: from basic research to clinical evidence
  publication-title: Ann Oncol
  contributor:
    fullname: Santini, D; Vespasiani Gentilucci, U; Vincenzi, B
– volume: 29
  start-page: 1125
  year: 2011
  end-page: 1132
  ident: B6
  article-title: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
  publication-title: J Clin Oncol
  contributor:
    fullname: Henry, DH; Costa, L; Goldwasser, F
– volume: 18
  start-page: 269
  year: 2004
  end-page: 278
  ident: B18
  article-title: Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities
  publication-title: BioDrugs
  contributor:
    fullname: Santini, D; Fratto, ME; Vincenzi, B; La Cesa, A; Dianzani, C; Tonini, G
– volume: 6
  start-page: 307
  year: 2006
  end-page: 312
  ident: B26
  article-title: Recent advances in understanding the mechanism of action of bisphosphonates
  publication-title: Curr Opin Pharmacol
  contributor:
    fullname: Coxon, FP; Thompson, K; Rogers, MJ
– volume: 353
  start-page: 99
  year: 2005
  ident: B5
  article-title: Osteonecrosis of the jaw and bisphosphonates
  publication-title: N Engl J Med
  contributor:
    fullname: Durie, BG; Katz, M; Crowley, J
– volume: 39
  start-page: 304
  year: 2009
  end-page: 316
  ident: B8
  article-title: Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment
  publication-title: Intern Med J
  contributor:
    fullname: Dickinson, M; Prince, HM; Kirsa, S
– volume: 69
  start-page: 2488
  year: 2011
  end-page: 2493
  ident: B30
  article-title: Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: López-Jornet, P; Camacho-Alonso, F; Martínez-Canovas, A; Molina-Miñano, F; Gómez-García, F; Vicente-Ortega, V
– volume: 194
  start-page: 51
  year: 2011
  end-page: 52
  ident: B11
  article-title: Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality
  publication-title: Med J Aust
  contributor:
    fullname: Sambrook, PJ; Nordin, BE; Goss, AN
– volume: 90
  start-page: 1339
  year: 2011
  end-page: 1345
  ident: B31
  article-title: A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw
  publication-title: J Dent Res
  contributor:
    fullname: Mawardi, H; Giro, G; Kajiya, M
– volume: 353
  start-page: 100
  year: 2005
  end-page: 101
  ident: B28
  article-title: Osteonecrosis of the jaw and bisphosphonates
  publication-title: N Engl J Med
  contributor:
    fullname: Maerevoet, M; Martin, C; Duck, L
– volume: 65
  start-page: 415
  year: 2007
  end-page: 423
  ident: B22
  article-title: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: Mavrokokki, T; Cheng, A; Stein, B; Goss, A
– volume: 28
  start-page: 5132
  year: 2010
  end-page: 5139
  ident: B29
  article-title: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study
  publication-title: J Clin Oncol
  contributor:
    fullname: Stopeck, AT; Lipton, A; Body, JJ
– volume: 61
  start-page: 1115
  year: 2003
  end-page: 1117
  ident: B20
  article-title: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: Marx, RE
– volume: 72
  start-page: 1938
  year: 2014
  end-page: 1956
  ident: B2
  article-title: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update
  publication-title: J Oral Maxillofac Surg
  contributor:
    fullname: Ruggiero, SL; Dodson, TB; Fantasia, J
SSID ssj0014453
Score 2.410548
Snippet Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity...
CONTEXT:Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable...
Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to...
CONTEXTMedication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable...
SourceID proquest
crossref
pubmed
wolterskluwer
endocrinepress
SourceType Aggregation Database
Index Database
Publisher
StartPage 3887
SubjectTerms Adult
Aged
Aged, 80 and over
Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology
Bone Density Conservation Agents - adverse effects
Bone Density Conservation Agents - therapeutic use
Dental Care - methods
Female
Humans
Incidence
Male
Middle Aged
Neoplasms - drug therapy
Retrospective Studies
Title Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer
URI http://dx.doi.org/10.1210/jc.2015-1794
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201510000-00036
https://www.ncbi.nlm.nih.gov/pubmed/26241323
https://search.proquest.com/docview/1720452494
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFB7WCmJR8e56YwR90pFcZpLMo1qlrVSFtlh8CZlLwFoTye5S8Ef5Gz1nZpLN2hWsLIQkHDKzOV9mzv0Q8jQ3uorTOmOZ0JLxKslZpSIDZzo1MpY2ijHfee9Dtn3Id4_E0WTyaxS1tJirl_rn2ryS_-Eq3AO-YpbsOTg7PBRuwDnwF47AYTj-E4-3rEtsdD5_7buDupAW53zBYZmLdQOZ8iMws20s7om-AAnKm7vVKZo7PvnSqhgJ6xKS4CndWGZFJI0KTAy5lLYxLaw5zbKK03c7B0yd9FUJ0XDjmzXvWPZ5mXO27zNqfFpQB7r60iT7uu2wfkLrzfUnsxYjdZ4PBup9i6aKro8hDmHJwWgRiyH8LVjSwgRtH5s6XqIxZiR3PdZhg_KrsuSC5bEP5B2W7Sga4zMarcJpETZxGy59E8YzuwWou7hbYCVLnGLu2y3_UX8btSQgLI91iWQlkl0gF5NcClT2t3beD14rzkPV0_AXQqIFZkmNB1kRga72zPKBz-sUnU1y5bTF2InZN5c6MRKADq6Ta0Fzoa88DG-QiW1ukkt7ITbjFvkyoJEOaKRtTc-ika6gEWkAjRTQSL82tEcjRTRSj8bb5PDd24M32yx07mCac54xBVuslkrwTGcFL3hSpejKS3RVaGvqxNSSw8pfGxEpqzKdqFgKa7TmUss0NekdstHAPO4RymWhUGYvTKS5KXKpCi4Vt7XIdAy_KXnWv8zyhy_QUq5j2ZS8WH3TZfhyZn8hf9LzoYQFF71oVWPbBVBjWyeRcKS56xk0DJxk6KZO0ilhKxwrfVJz6TRyEA8ZjuM8a8xVhLp_vsk9IJeXH9VDsjHvFvYRyMZz9dgB8jfoJrlO
link.rule.ids 315,786,790,27957,27958
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Declining+Incidence+of+Medication-Related+Osteonecrosis+of+the+Jaw+in+Patients+With+Cancer&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Sim%2C+Ie-Wen&rft.au=Sanders%2C+Kerrie+M&rft.au=Borromeo%2C+Gelsomina+L&rft.au=Seymour%2C+John+F&rft.date=2015-10-01&rft.pub=Endocrine+Society&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=100&rft.issue=10&rft.spage=3887&rft.epage=3893&rft_id=info:doi/10.1210%2Fjc.2015-1794&rft.externalDocID=10_1210_jc_2015_1794
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon